Search Filters

Search Results

Found 2 results

510(k) Data Aggregation

    K Number
    K201989
    Device Name
    B4C System
    Date Cleared
    2021-10-08

    (448 days)

    Product Code
    Regulation Number
    882.1620
    Reference & Predicate Devices
    Why did this record match?
    Applicant Name (Manufacturer) :

    Braincare Desenvolvimento e Inovacao Tecnologica S.A.

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The B4C System is intended for the monitoring of variation in intracranial pressure in patients with suspected alteration of intracranial pressure (ICP) or change in intracranial compliance, by providing surrogate ICP waveforms and associated parameters (estimated P2/P1 ratio, normalized Time-to-Peak, derived useful ICP pulses and cardiac pulses) for interpretation.

    Device Description

    The B4C System is a non-invasive device intended for the monitoring of variation in intracranial pressure, including patients with suspected alteration of intracranial pressure (ICP) or change in intracranial compliance. It consists of a sensor with Bluetooth wireless module, headband, mobile device software application, receiver, external battery pack and charger, as well as processing and analytical software. The sensor contains four strain gauges situated on a metal bar that detects variations in skull deformation through tension and compression of the metal bar in response to changes in intracranial pressure. These resistance measures are converted to a digital signal using a high-resolution ADC (Analog to Digital Converter) in the sensor that is transmitted to software components for viewing, processing and analysis. The proposed device does not measure absolute intracranial pressure values, but produces surrogate waveform morphology, its trend, and associated parameters reflecting changes in ICP. The B4C System and surrogate waveform and associated outputs do not substitute ICP monitoring methods when measurement of the absolute value of ICP is required to make a clinical decision.

    AI/ML Overview

    Here's a breakdown of the acceptance criteria and the study that proves the B4C System meets them, based on the provided FDA 510(k) summary:

    Acceptance Criteria and Reported Device Performance

    The acceptance criteria for the B4C System's clinical performance are implicitly derived from the study objectives and the statistical analyses performed. The primary objective was to demonstrate a "consistent correlation" and "reliability and accuracy of the correlation" between the B4C System's surrogate ICP waveform and parameters and those from invasive ICP monitoring.

    Acceptance Criteria (Implicit)Reported Device Performance
    P2/P1 Ratio Correlation: Statistically significant correlation with invasive ICP monitoring.Spearman correlation: 0.495 [0.471, 0.517], p0.7.
    Normalized Time-to-Peak (TTP) Correlation: Statistically significant correlation with invasive ICP monitoring.Spearman correlation: 0.318 [0.291, 0.345], p0.2.
    Safety: No serious adverse events related to the device.No adverse events were reported.
    Substantial Equivalence: Demonstrate comparable performance to predicate device with respect to ICP waveform morphology monitoring.The study concluded that results demonstrated a statistically significant correlation in the ICP signal and waveform parameters between the B4C System and the gold standard invasive ICP monitoring device. The outcomes demonstrate comparable effectiveness between the Braincare device and commonly used invasive ICP devices for monitoring and assessing variations in ICP waveform associated parameters over time. Based on performance testing and comparison, it was deemed substantially equivalent to the predicate device.

    Detailed Study Information:

    1. Sample sizes used for the test set and data provenance:

      • Total enrolled subjects: 123
      • Subjects after device label check: 107
      • Subjects after data quality check: 85 (78 adults, 7 pediatric)
      • Analyzed participants (test set): 78 adults (due to reduced quantity of pediatric subjects, enabling statistically relevant performance only for adults).
      • Total acquisition time analyzed: 4695 minutes (98% adult, 2% pediatric across the broader dataset).
      • Data Provenance: Not explicitly stated, but the mention of "4 centers" suggests a multi-center study. The sponsor is Braincare Desenvolvimento e Inovacao Tecnologica S.A. based in Brazil, suggesting the origin of the data is likely within Brazil or other international sites. The study was described as "combined prospective, multi-center, observational study."
    2. Number of experts used to establish the ground truth for the test set and qualifications of those experts:

      • The document implies that the ground truth was established using "gold standard invasive ICP monitoring methods such as the external ventricular drain or intraparenchymal micro transducers."
      • It does not explicitly state the number of experts or their qualifications for establishing the ground truth from these invasive methods. It relies on the inherent validity of the invasive measurements as the "gold standard."
    3. Adjudication method for the test set:

      • No adjudication method (e.g., 2+1, 3+1) is mentioned for the test set ground truth. The ground truth was established directly from invasive ICP devices. This type of data does not typically involve multiple human readers or adjudication in the same way as, for example, image interpretation.
    4. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:

      • No, a multi-reader multi-case (MRMC) comparative effectiveness study was not explicitly performed or described. This study focused on the technical correlation and agreement between the device's output and invasive ICP measurements. It did not directly assess the impact of the B4C System on human reader performance or diagnostic accuracy.
    5. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done:

      • The study primarily focused on the standalone performance of the B4C System's ability to produce surrogate ICP waveforms and associated parameters that correlate with invasive ICP measurements. The analysis (Spearman correlation, normalized mutual information, Bland-Altman, Deming regression) evaluates this algorithm-only performance.
      • The device is intended to provide "surrogate ICP waveforms and associated parameters... for interpretation," implying a human-in-the-loop for interpretation, but the study itself is about the accuracy of the device's output compared to ground truth.
    6. The type of ground truth used:

      • Objective/Physiological Data: The ground truth was established using "gold standard invasive ICP monitoring methods such as the external ventricular drain or intraparenchymal micro transducers." This represents direct physiological measurement rather than expert consensus on subjective interpretation.
    7. The sample size for the training set:

      • The document does not specify a separate training set size. The clinical study described appears to be a validation study (test set) for the pre-existing B4C System, which includes processing and analytical software. Given the description, the models and algorithms within the B4C System would have been developed and trained using other data, but that training data and its size are not disclosed in this 510(k) summary.
    8. How the ground truth for the training set was established:

      • As the training set details are not provided, the method for establishing its ground truth is also not described in this document.
    Ask a Question

    Ask a specific question about this device

    K Number
    K182073
    Date Cleared
    2019-10-17

    (442 days)

    Product Code
    Regulation Number
    882.1620
    Reference & Predicate Devices
    Why did this record match?
    Applicant Name (Manufacturer) :

    Braincare desenvolvimento e Inovacao Tecnologica S.A.

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The BcSs-PICNI-2000 Sensor is intended for the monitoring of variation in intracranial pressure in patients with suspected alteration of intracranial pressure (ICP) or change in brain compliance, by providing ICP waveforms for interpretation.

    Device Description

    The BcSs-PICNI-2000 Sensor ("the Braincare Sensor") is a non-invasive device intended for the monitoring of variation in intracranial pressure, including patients with suspected alteration of intracranial pressure (ICP) or change in brain compliance. It consists of a sensor, headband, and adapter cable. The sensor contains four strain gauges situated on a metal bar that detects variations in skull deformation through tension and compression of the metal bar in response to changes in intracranial pressure. The proposed device does not measure absolute intracranial pressure values, but produces waveform morphology and its trend reflecting changes in ICP. The BcSs-PICNI-2000 Sensor and waveform output do not substitute ICP monitoring methods when measurement of the absolute value of ICP is required to make a clinical decision.

    The sensor component is supported on a plastic headband worn by the patient, such that the sensor is in contact with the scalp and is perpendicularly positioned in the temporoparietal transition, 2 inches (5-6 cm) above the entrance of the external auditory canal on the coronal plane. Slight pressure is applied so that the sensor pin maintains contact with the scalp throughout the monitoring session. The sensor continuously records and transfers acquired signals through an adapter cable to a compatible multi-parameter monitor that has piezoresistive pressure transducer sensitivities of 5uV/Vex/mmHg or greater and automatic amplitude window adjustment capability. The multi-parameter monitor's inherent software interprets the signal received from the BcSs-PICNI-2000 Sensor and displays a waveform that allows for assessment of suspected intracranial hypertension or changes in brain compliance based on the characteristic Percussion (P1), Tidal (P2), and Dicrotic (P3) peaks of the ICP waveform morphology.

    The BcSs-PICNI-2000 Sensor is not intended to be a standalone diagnostic tool. The waveform output does not replace a comprehensive clinical evaluation, but only provides an element for preliminary assessment. The clinician is responsible for determining the additional clinical information that may be required to make a diagnosis.

    AI/ML Overview

    Here's an analysis of the acceptance criteria and the studies performed for the BcSs-PICNI-2000 Sensor, based on the provided document:

    Acceptance Criteria and Device Performance

    The document doesn't explicitly state a table of "acceptance criteria" with specific thresholds for performance metrics. Instead, it details various tests and their "Pass" or "Results" that demonstrate the device meets expected performance and safety standards, largely by showing substantial equivalence or demonstrating proper functioning. The "Results" column in the table below is derived from the Table 3 Summary of Non-Clinical Performance Data and the Study Outcomes sections of the clinical studies.

    Test / Performance MetricAcceptance Criteria (Implicit)Reported Device Performance
    Biocompatibility
    In vitro cytotoxicityNon-cytotoxicPass: Non-cytotoxic
    Irritation & skin sensitizationNon-sensitizing, Non-irritatingPass: Non-sensitizing, Non-irritating
    Electrical Safety & EMC
    IEC 60601-1Compliance with standardPass
    IEC 60601-1-2Compliance with standardPass
    Disinfection
    Low-Level disinfection method (70% ethanol)6-log microbial reductionPass: 6-log microbial reduction
    Bench Testing
    Monitor CompatibilityCompatible with patient monitorsPass
    Stability and Reproducibility (waveform)Stable and reproducible waveform characteristicsExcellent stability, some variance in reproducibility.
    Animal Studies
    Rat Model (iICP vs. nICP correlation)Positive correlation (r > 0)Pearson's correlation coefficient r = 0.8 ± 0.2 (positive correlation)
    Swine Model (iICP vs. nICP correlation)Positive correlation (r > 0)Spearman's correlation coefficient r = 0.81 ± 0.24 (positive correlation)
    Clinical Studies (Observational)
    HIV-associated Cryptococcal Meningitis (waveform changes consistent with clinical status)Waveform morphology indicative of clinical status and response to treatmentWaveforms showed P2>P1 with neurological symptoms, P1P2>P3 resembling normal brain compliance post-treatment; consistent with clinical status.
    Traumatic Brain Injury (iICP vs. nICP similarity)Greater similarity between iICP-nICP than nICP-ABP (statistically significant)Difference between iICP-nICP and nICP-ABP statistically significant for all 7 patients (p
    Ask a Question

    Ask a specific question about this device

    Page 1 of 1